Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Liminal BioSciences Inc. LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by Mackinnon80on Jun 24, 2015 10:11pm
230 Views
Post# 23866208

RE:RE:Plasminogen and (diabetic) chronic wound

RE:RE:Plasminogen and (diabetic) chronic woundYou are absolutely right Bepando...plasminogen is the key for PLI. Everything will start to flow once we get the FDA approval for T1 hypoplasminogenia (derisking the whole PPPS platform for large investors).

I know it's way too early to discuss this but if plasminogen one day gets approved for treating serious chronic wounds, I wonder how PLI would address the huge need (in term of grams of plasminogen extracted per year). Given the size of serious chronic wounds market...and the fact that they will first have to address T1 plasminogen deficiency, that would probably be impossible for PLI to produce enough plasminogen IV dose with "only" one (or even with two) millions of liter per year...for both indication.

Well maybe this would be the start of a new era for the PPPS technology development. Who would try to extract it with the Cohn technology when the yield (for plasminogen) is only 35 % (purity is not known but it's fair to assume that it is lower than the 70 % obtained with PPPS).

M80
Bullboard Posts

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse